Alixorexton, a Novel Oral Orexin 2 Receptor Agonist, Shows Promising Safety and Efficacy in Narcolepsy Type 1: Insights from the Vibrance-1 Phase 2 Trial

MedXY Editorial Team•Aug 26, 2026•Neurology

Alixorexton, a selective oral orexin 2 receptor agonist, significantly improves wakefulness in patients with narcolepsy type 1 compared to placebo, as evidenced by increased mean sleep latency on the Maintenance of Wakefulness Test.
Clinically meaningful reduction in excessive daytime sleepiness and cataplexy symptoms was observed after six weeks of daily dosing across multiple doses (4 mg, 6 mg, 8 mg).
The safety profile of alixorexton was generally acceptable; adverse events aligned with known on-target OX2R agonist effects and were manageable.
Vibrance-1 trial results strongly support advancing alixorexton into phase 3 studies, offering a promising new therapeutic option for narcolepsy type 1 patients.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Alixorexton, a selective oral orexin 2 receptor agonist, significantly improves wakefulness in patients with narcolepsy type 1 compared to placebo, as evidenced by increased mean sleep latency on the Maintenance of Wakefulness Test.
Clinically meaningful reduction in excessive daytime sleepiness and cataplexy symptoms was observed after six weeks of daily dosing across multiple doses (4 mg, 6 mg, 8 mg).
The safety profile of alixorexton was generally acceptable; adverse events aligned with known on-target OX2R agonist effects and were manageable.
Vibrance-1 trial results strongly support advancing alixorexton into phase 3 studies, offering a promising new therapeutic option for narcolepsy type 1 patients.